Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1

Conditions

Prostatic Neoplasms 22Neoplasm Metastasis 2Small Cell Lung Carcinoma 1Salivary Gland Neoplasms 1Prostate Adenocarcinoma 1Newly Diagnosed Oligometastatic Prostate Cancer 1Castration Levels of Testosterone 1Carcinoma, Small Cell 1Bulbo-Spinal Atrophy, X-Linked 1

Interventions

enzalutamide 3pembrolizumab 1nilutamide 1bicalutamide 1apalutamide 1Vorinostat 1Tamoxifen 1Panobinostat 1Dasatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Bulbo-Spinal Atrophy, X-Linked × apalutamide × Clear all
NCT04926181 2025-05-15

Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer

University of California, San Francisco

Phase 2 Terminated
2 enrolled 12 charts
GenitourinaryThoracic

Prostatic Neoplasms, Carcinoma, Small Cell, Bulbo-Spinal Atrophy, X-Linked, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡